Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970941 | PMC |
| http://dx.doi.org/10.1097/FPC.0000000000000232 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring the Effect of Gomisin A on Non-Small Cell Lung Cancer With Network Pharmacology, Molecular Docking, In Vitro and In Vivo Assays.
Chem Biol Drug Des
November 2024
Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China.
Gomisin A is an active ingredient of Schisandra chinensis. Pre-clinical studies suggest Gomisin A has good anti-cancer activities against a variety of cancers, but its mechanism of action in non-small cell lung cancer (NSCLC) is unclear. This study aims to explore the potential mechanism of Gomisin A in treating NSCLC.
View Article and Find Full Text PDFPharmVar GeneFocus: CYP4F2.
Clin Pharmacol Ther
October 2024
Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Research Institute (CMRI), Kansas City, Missouri, USA.
The Pharmacogene Variation Consortium (PharmVar) serves as a global repository providing star (*) allele nomenclature for the polymorphic human CYP4F2 gene. CYP4F2 genetic variation impacts the metabolism of vitamin K, which is associated with warfarin dose requirements, and the metabolism of drugs, such as imatinib or fingolimod, and certain endogenous compounds including vitamin E and eicosanoids. This GeneFocus provides a comprehensive overview and summary of CYP4F2 genetic variation including the characterization of 14 novel star alleles, CYP4F2*4 through *17.
View Article and Find Full Text PDF[Mechanism of bulleyaconitine A in inhibiting bone destruction of rheumatoid arthritis via Src/PI3K/Akt signaling pathway].
Zhongguo Zhong Yao Za Zhi
March 2024
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China.
Article Synopsis
- The study investigates how bulleyaconitine A affects bone destruction in rheumatoid arthritis through the Src/PI3K/Akt signaling pathway.
- Researchers identified key RA targets and bulleyaconitine A's potential targets using various databases, and conducted analyses to understand their interactions and functions.
- Experimental results show that bulleyaconitine A inhibited the expression of genes linked to osteoclast differentiation, indicating its potential as a treatment for RA-related bone damage.
PillHarmonics: An Orchestrated Pharmacogenetics Medication Clinical Decision Support Service.
Appl Clin Inform
March 2024
Elimu Informatics, El Cerrito, California, United States.
Objectives: Pharmacogenetics (PGx) is increasingly important in individualizing therapeutic management plans, but is often implemented apart from other types of medication clinical decision support (CDS). The lack of integration of PGx into existing CDS may result in incomplete interaction information, which may pose patient safety concerns. We sought to develop a cloud-based orchestrated medication CDS service that integrates PGx with a broad set of drug screening alerts and evaluate it through a clinician utility study.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!